Entecavir and tenofovir disoproxil fumarate for the treatment of chronic hepatitis B in adults with decompensated liver disease (discontinued)
 
Status Discontinued
Process MTA
Topic area
  • Digestive system
  • Infectious diseases

Provisional Schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
2nd appraisal committee meeting: TBC

Project Team

Communications manager: TBC
Executive Lead: TBC
Project manager: TBC
Technical Lead: TBC

Timeline

Key events during the development of the guidance:

Date Update
29 March 2011

The treatment of chronic hepatitis B in adults with cirrhosis, including those with liver decompensation is included in the scope of the Clinical Guideline Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young people and adults.

Therefore, the appraisal of entecavir and tenofovir disoproxil fumarate for the treatment of chronic hepatitis B in adults with decompensated liver disease has been un-referred from the NICE technology appraisal work programme.

8 March 2011

Following the additional draft scope consultation, further discussions with the Department of Health and noting the overlap between the Technology Appraisal and the recently referred Clinical Guideline; The diagnosis and management of hepatitis B in children, adolescents and adults, it has been decided that the Technology Appraisal will be suspended until the outcome of the scoping process for the Clinical Guideline is known.

Please see cg165 for more information regarding the Clinical Guideline of ‘The diagnosis and management of hepatitis B in children, adolescents and adults’.

6 May 2010

Please note that this appraisal is now expected to start inapproximately early December 2010.

The deadline for submissions is expectedin approximately late March 2011.


For further information on how we develop guidance, please see our page about NICE technology appraisal guidance